Lexaria Bioscience (LEXX) Stock Forecast: StockMap's 2-Week Call

LEXX stock forecast: StockMap's model calls Lexaria Bioscience Strong Underperform for the two weeks after the Nov 19 close: it expects LEXX to trail the growth index. It is a call on the gap, not a price target. Right in 4 of 6 two-week windows on LEXX since Aug 21; by chance, a call on the same dates was right 59% of the time.

Lexaria Bioscience last closed at $4.49, +4.91% on the session.

Against the IVW growth benchmark the position is +7.24% over the forecast window.

Lexaria Bioscience's market cap is $9.46M as of November 19, 2026.

Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -51 (behind).

Where LEXX sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

49 daily calls for LEXX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Lexaria Bioscience is classified under Health Care / Pharmaceuticals.

StockMap tracks Lexaria Bioscience as the 131st largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.

On that composite Lexaria Bioscience ranks 127th of 153 in the group, against a group median of -0.36.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Lexaria Bioscience (LEXX) — StockMap 2-week forecast & tracked accuracy